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ABSTRACT 
 
Stroke is one of the most leading causes of death and disability in the world. Complement 
system activation contributes to pathogenesis and neuronal damage following stroke. There 
are no defined biological serum markers to determine the severity of stroke in acute phases. 
The purpose of current study was to determine the association of three complement 
activators, namely Pentraxin-3 (PTX3), M-ficolin, and Surfactant protein A (SPA) with the 
severity of ischemic stroke. 
This cross-sectional study was done on 82 patients diagnosed with ischemic stroke at 24-
96 hours of initiation of the clinical symptoms during 2014-2015. The serum levels of PTX3, 
M-ficolin, and SPA were measured by enzyme-linked immunosorbent assay (ELISA). The 
patients were divided in three stroke severity groups according to modified National Institute 
of Health Stroke Scale mNIHSS.  
The results showed that the more severity of the stroke was, the higher serum levels of 
three evaluated molecules (p<0.001) were. The correlation of serum level of PTX3, M-
ficolin, and SPA with stroke severity was 0.732, 0.736, and 0.731, respectively.  
There is a strong association between serum levels of PTX3, M-ficolin, and SPA with the 
severity of ischemic stroke. Clinically, such association may be considered to evaluate the 
severity of the ischemic stroke. 
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INTRODUCTION 
 
Stroke is one of the most leading causes  
of disability and mortality in the world.
1
 The  
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complement, cascade is an effector arm of innate 
immune system which is activated via three main 
pathways, namely alternative, classic, and mannose-
binding lectin (MBL). The latter is importantly activated 
in the pathogenesis of the ischemic stroke.
2
 Multiple 
activators of complement are present in injured tissue 
and contribute to the release of inflammatory mediators, 
opsonophagocytosis, killing of pathogens, and removal 
of damaged host cells.
2
 Recently some clinical studies 
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provided evidence supporting activation of complement 
cascade in acute ischemic stroke
2-4
 that contributed in 
larger brain infarction and worsening of neurological 
deficits.
2,5-7
 Depletion of complement system in some 
rodent and human studies has been considered as a 
therapeutic target
8
 that could improve outcome, 
neurologic deficit, and infarct size of the stroke.
2,6,9
 
Many studies evaluating the association of 
complement and stroke, have shown the alteration of 
different complement markers such as c3, c4,
 4, 5, 10-12
 C-
reactive protein (CRP),
3,13
 C1q and C1q inhibitor (c1q 
INH),
9,12,14,15
 and MBL
2,4
 after stroke. Recently, some 
studies have investigated newer complement molecules 
such as pentraxin3 (PTX3)
16
 and ficolins,
17,18
 after stroke 
to determine some more sensitive and specific markers.  
PTX3, one long pentraxin that conserves the c-
terminal domain of the classical short pentraxins like 
CRP but differs because of having an unrelated long N-
terminal domain, is one of the pattern-recognition 
receptors implicated in initial steps of complement 
cascade activation prior to CRP.
16
 Release of PTX3 from 
macrophages, neutrophils, endothelial and smooth 
muscle cells appears to be in response to infectious or 
non-infectious inflammatory states like atherosclerosis.
19
 
Considering its interaction with atherosclerosis 
conditions such as acute myocardial infarction and 
unstable angina,PTX3 could have a superior prognostic 
value compared to CRP, Troponin-T (TnT), and ceratin 
kinase (CK).
19,20
 Although one study showed such 
prognostic value after stroke,
16
 but its association with 
stroke severity was unclear. 
Lectin pathway, which is activated by MBL and 
ficolins, is the main complement pathway responsible 
after stroke.
18
 There are three types of ficolins: M-ficolin 
(monocyte) or ficolin-1, L-ficolin (liver) or ficolin-2, and 
H-ficolin (Hakta antigen) or ficolin-3. Study of George 
Fust et al. demonstrated a negative correlation between 
ficolin-3 and stroke in such a way that low ficolin-3 
levels were associated with unfavorable outcome after 
stroke.
18
 We found no more studies evaluating the 
association of M-ficolin with stroke severity and its 
outcomes. 
Pulmonary surfactants are lipoproteins synthesized 
by type II alveolar cells that reduce surface tension at 
alveolar-air interface. Four main surfactant proteins have 
been recognized: surfactant protein (SP) A, SPB, SPC, 
and SPD. SPA, which is the major component of 
surfactant proteins as well as a member of collectin 
family of C-type lectins, plays some roles in innate 
immunity of lungs via imitating C1q in activation of 
classical complement pathway. SPA is also found in 
some other tissues like prostate, spleen, mesothelium, 
gastrointestinal tract, and synovial;
21
 but there is no 
available data in brain after stroke.  
The purpose of this study was to determine the 
association of the serum levels of three complement 
molecules of PTX3, M-ficolin, and SPA, each related to 
one pathway, with the severity of ischemic stroke. 
Evaluating such association may suggest some new 
pharmacologic as well as prognostic markers of ischemic 
stroke.  
 
MATERIALS AND METHODS 
 
Our cross-sectional study was conducted on 89 adult 
patients older than 21 years suffering from ischemic 
stroke during 2014-2015 at emergency department of 
Shahid Beheshti Hospital of Kashan. The diagnosis was 
made according to clinical symptoms as well as signs 
and also brain computed tomography (CT) and magnetic 
resonance imaging (MRI) after 24-96 hours of emerging 
clinical symptoms. Patients with any acute infection or 
inflammatory state, acute myocardial infarction, and 
renal failure (GFR<30) were excluded. Three patients 
were excluded because of rheumatoid arthritis, 
hemorrhagic stroke, hemolysis of blood sample, and four 
patients due to sepsis after stroke. Finally, 82 patients 
completed the study. The ethical committee of the 
Kashan University of Medical Sciences approved the 
project and informed consent was obtained from each 
patient or patient’s kin according to patient general 
condition.  
Serum samples were obtained from all patients at 24-
96 hours after emerging of stroke symptom and stored 
immediately at -80 centigrade until the assays were 
performed. Serum levels of PTX3, M-ficolin, and SPA 
were measured by Cusibo kit, (England), using a 
sandwich enzyme linked immunosorbent assay (ELISA) 
method according to manufacturer’s protocol. CRP 
levels were measured by the agglutination method. 
Patient’s demographic data (age, sex) and traditional 
risk factors including hypertension, diabetes, 
hyperlipidemia, current smoking, history of previous 
stroke or transient ischemic attack (TIA), history of 
coronary vascular disease, and current consumption of 
aspirin or warfarin were obtained. The severity of stroke 
was scored on admission time according to modified 
National Institute of Health Stroke Scale (mNIHSS).
22
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The mNIHSS consists of 11 items and 31 total scores. 
Score of 1-5 was considered as minor, 6-14 as moderate, 
and 15-31 as severe stroke.
23
 
The data were analyzed by SPSS17 SPSS Inc., 
Chicago, IL, USA).A p. value<0.05 was considered 
significant. Pearson’s correlation test and Spearman’s 
test were used according to data distribution to determine 
linear relationship between the variables. Independent t-
test determined differences between the groups and 
ANOVA test was used to evaluate the association 
between the complement markers and stroke severity. 
 
RESULTS 
 
Baseline and clinical characteristics of study 
population are summarized in Table1.  
The mean serum levels of PTX3, M-ficolin, and SPA 
 
 in different severities of mild, moderate, and severe 
stroke are shown in Table 2. The more severe the stroke 
was, the higher levels of serum level of PTX3, M-ficolin, 
and SPA (p<0.001) were. 
There was a significant correlation between PTX3, M-
ficolin, and SPA with stroke severity according to 
mNIHSS score (p<0.001) (Table 3). The mean serum 
level of CRP increased in line with the stroke severity 
(p=0.022) which is lower than our three considered 
markers (Table 3). Such association of different markers 
remained significant even at the presence of confounding 
effects of age, diabetes, hypertension, hyperlipidemia, 
smoking, and stroke/TIA history in multivariate 
regression model (Table 4). Every unit increase in the 
level of mNIHSS increased the serum level of PTX3 as 
0.47, M-ficolin as 0.08 and SPA as 4.9 units in 
regression model.  
Table1. Demographic and clinical characteristics of patients with ischemic stroke  
Variable  Description N (%) p. value 
Age  (Mean±SD) 70.2±14.3 - 
Sex  Male 42 (51.2%) 0.55 
female 40 (48.8%) 
Diabetes mellitus Yes 25 (30.5%) 0.566 
No 57 (69.5%) 
Hypertension  Yes 51 (62.2%) 0.176 
No 31 (37.8%) 
Hyperlipidemia  Yes 24 (29.3%) 0.52 
No 58 (70.7%) 
Stroke/TIA history Yes 17 (20.7%) 0.32 
No 65 (79.3%) 
CVD History Yes 22 (26.8%) 0.133 
No 60 (73.2%) 
Anticoagulant  ASA 25 (30.5%) 0.958 
Warfarin 6 (7.3%) 
Non 51 (62.2%) 
Smoker  Yes 13 (15.9%) 0.542 
Previous 2 (2.4%) 
No 67 (81.7%) 
mNIHSS Mean±SD 8.26±5.58 - 
PTX3 Mean±SD 7.15±3.66 - 
M-ficolin Mean±SD 1.49±0.61 - 
SPA Mean±SD 88.29±37.13 - 
CRP Mean±SD 15.52±19.25 - 
Stroke severity Mild 37 (45.1%)  
- Moderate 27 (32.9%) 
Severe 18 (22.0%) 
SD, standard deviation; TIA ,transient ischemic attack; CVD, coronary vascular disease; mNIHSS , modified national institute of health 
stroke scale; PTX3, pentraxin 3; M-ficolin, monocyte ficolin; SPA, surfactant protein A; CRP ,C-reactive protein; ASA, acetyl salicylic acid;
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Table 2. Mean serum level of PTX3, M-ficolin, SPA, and CRP in different stroke severities (mNIHSS) 
Stroke severity 
Molecules 
Mild 
(Mean±SD) 
Moderate 
(Mean±SD) 
Severe 
(Mean±SD) 
p* 
PTX3 (pg/ml) 4.53±1.42 8.18±3.18 10.98±3.47 <0.001 
M-ficolin (pg/ml) 1.06±0.31 1.60±0.48 2.21±0.52 <0.001 
SPA (pg/ml) 67.98±16.36 85.47±29.19 134.27±42.49 <0.001 
CRP (mg/l) 10.38±11.16 18.74±19.68 21.23±28.31 0.047 
*ANOVA test; PTX3, pentraxin 3; M-ficolin, monocyte ficolin; SPA, surfactant protein A; CRP, C-reactive protein; mNIHSS, 
modified national institute of health stroke scale 
 
Table 3. Correlation of PTX3, M-ficolin, SPA, and CRP with stroke severity (Pearson’s correlation test) 
Variable Correlation Sig. 
PTX3* 0.723 <0.001 
M-ficolin** 0.736 <0.001 
SPA*** 0.731 <0.001 
CRP**** 0.253 0.022 
*dependent variable: PTX3 **dependent variable: M-ficolin  ***dependent variable: SPA ****dependent variable: CRP 
PTX3, pentraxin 3; M-ficolin, monocyte ficolin; SPA, surfactant protein A; CRP ,C-reactive protein;  
 
Table 4. Association of serum levels of PTX, M-ficolin, SPA and CRP with mNIHSS in separate multivariate models 
Outcome Model  Unstandardized Coefficients Standardized Coefficients t Sig. 
B Std. Error Beta 
PTX3* (Constant) 2.425 1.640  1.479 0.144 
mNIHSS 0.470 0.057 0.716 8.254 0.000 
Age  0.016 0.021 0.064 0.762 0.449 
Sex  -0.865 0.748 -0.119 -1.157 0.251 
Stroke history -0.159 0.739 -0.018 -0.215 0.830 
DM 0.379 0.684 0.048 0.555 0.580 
HTN -0.201 0.685 -0.027 -0.293 0.770 
Hyperlipidemia  -0.507 0.735 -0.063 -0.690 0.493 
Smoking  1.604 0.720 0.203 2.228 0.029 
M-ficolin** (Constant) 0.683 0.269  2.541 0.013 
mNIHSS 0.079 0.009 0.725 8.514 0.000 
Age  0.002 0.004 0.041 0.501 0.618 
Sex  0.060 0.123 0.050 0.491 0.625 
Stroke history -0.071 0.121 -0.047 -0.587 0.559 
DM -0.087 0.112 -0.066 -0.780 0.438 
HTN 0.054 0.112 0.043 0.478 0.634 
Hyperlipidemia  0.144 0.121 0.107 1.191 0.238 
Smoking  -0.179 0.118 -0.136 -1.514 0.134 
SPA*** (Constant) 58.240 16.609  3.507 0.001 
mNIHSS 4.873 0.577 0.733 8.451 0.000 
Age  -0.092 0.217 -0.036 -0.424 0.673 
Sex  -11.452 7.577 -0.155 -1.511 0.135 
Stroke history 2.445 7.482 0.027 0.327 0.745 
DM -0.891 6.924 -0.011 -0.129 0.898 
HTN 1.466 6.942 0.019 0.211 0.833 
Hyperlipidemia  -2.356 7.444 -0.029 -0.316 0.753 
Smoking  8.083 7.291 0.101 1.109 0.271 
*dependent variable: PTX3 **dependent variable: M-ficolin  ***dependent variable: SPA PTX3, pentraxin 3; M-ficolin, 
monocyte ficolin; SPA, surfactant protein A; CRP ,C-reactive protein; mNIHSS, modified national institute of health stroke scale; 
DM, diabetes mellitus; HTN, hypertension;  
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DISCUSSION 
 
Complement system, one of the most important 
components of immune system, contributes also in 
stroke pathogenesis.
2,3
 It seems that inhibition of 
complement system could reduce the size of infarcted 
area as well as neurologic damage.
2,6
 Our study 
demonstrated, to best of our knowledge for the first 
time, a strong correlation between 3 molecules of 
PTX3, M-ficolin, and SPA with stroke severity score. 
Such correlation was stronger than that of well-known 
inflammatory molecule CRP and remained significant 
even after adjusting the effect of confounders. This 
concept may introduce those complement activators as 
clinically valuable markers to determine stroke severity 
in acute phases. It is likely that in more severe types of 
stroke, more de novo or induced production of such 
markers, as a manifestation of their inflammatory 
function, constitutes a circulatory reservoir that 
supplies their CNS-consumed quantities.
24,25
 
 In line with our study, Wi-sun Ryu et al. showed 
higher levels of PTX3 which was independently 
associated with increased mortality after ischemic 
stroke. They also introduced PTX3 as a more predictive 
marker of mortality than age, CRP, and mNIHSS as 
stroke severity score. The combination of PTX3 and 
NIHSS had higher discriminatory accuracy than PTX3 
and NIHSS alone.
16
 Similar to stroke events, the 
relationship of PTX3 activation with atherosclerosis 
progression has mostly been studied in coronary 
vascular diseases.
16,19,26-28
 Some studies suggest that 
deficiency of PTX3 is associated with increased cardiac 
damage and mortality. Therefore, PTX3 may 
potentially play some cardiovascular protective 
roles.
28,29
 According to this idea, increased serum levels 
of PTX3 in our study may be a compensatory 
mechanism to overcome the severity of stroke through 
its neurogenic as well as angiogenic effects which 
improves motor function.
30
 Paradoxically, others 
believe that PTX3 has some pro-inflammatory effects 
which lead to damaging consequences of inflammation 
and in this regard it is associated with  
poor outcomes. So anti-infalmmatory or 
proinflammatory role of PTX3 is challenging  .
16,19,26,27
 
Latter idea supports increased amounts of PTX3 in our 
study as a pathologic marker causing more severe 
forms of stroke.  
In consistence with other studies,
12,18,31
 our study 
supports the role of lectin pathway in the pathogenesis 
of stroke. However, changes in serum level of ficolins 
after stroke seem to be different, regarding the severity 
as well as outcomes of stroke. For example George 
Fust et al. showed a decreased concentration of both H 
and L-ficolin in admission time as well as early follow-
up of patients with ischemic stroke compared to healthy 
subjects,
18
 and R. Zangari et al found a decreased (at 6 
hours) and then, in agreement with our study (in the 
case of M-ficolin), increased (at 48 hours) 
concentration of both M and L-ficolins and consistent 
decreased levels of H-ficolin at both times after the 
ischemic stroke.
25
  George Fust et al found an inverse 
correlation between H-ficolin concentration and stroke 
severity according to  mNIHSS stroke scale, infarction 
size, and worsen outcome, and  
 R. Zangari et al revealed a selective inverse 
relationship between L-ficolin concentrations at 6-
hours after the stroke and 3-month unfavorable 
outcomes. The reverse relationship between H and L-
ficolins and stroke severity could be due to their local 
consumption in acute stroke. However, we showed a 
positive correlation between the serum levels of M-
ficolin measured 24-96 hours after the stroke with 
stroke severity. Like previous findings,
3,13,32,33
 this 
study also revealed a higher association of CRP level 
with poor outcomes. 
Current study demonstrated that serum level of SPA 
goes up with increasing stroke severity. Previous 
studies have shown activation of SPA, one of the 
complement activators, in (the inflammation of) some 
tissues like alveolus, prostate, spleen, and 
mesothelium.
21
 It seems that more studies are required 
to evaluate SPA activity after stroke. 
 The limitation of our study was that the serum 
concentrations were measured once in acute phase and 
there were no longitudinal follow-up samples to 
evaluate their changes during the time. This limitation 
allowed just a cross-sectional analysis with only a 
limited robustness.  
Our three studied complement molecules showed a 
strong correlation with stroke severity. Such correlation 
was even more than CRP. These findings may be used 
for both diagnostic approaches of stroke severity and 
therapeutic strategies. 
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